Due to their specific efficacy, safety and resistance profile, new combined antiretroviral therapies could potentially be administered before the results of genotype profiling, allowing for treatment of patients immediately after diagnosis which in turn limits disease transmission.
We developed a transmission model to determine the possible impact of test & treat with novel cART at the population level in France by modelling the impact of quicker treatment initiation on HIV transmission and reduced rates of lost to follow-up patients.
G Pialoux, C Delaugerre, S Gallien, G Gras, M Massetti, H Leleu, M Blachier, I Rodriguez. Impact de la stratégie « dépister et traiter » (test & treat) et du traitement immédiat sur l’incidence du VIH en France : Résultats d’un modèle de transmission. Poster Presentation at SFLS 2018, Reims FRANCE.
Eddowes L, Haskins-Coulter T, Painter C, Jandu S, Wild L, Kearns S, Massetti M. Modelling the effect of rapid treatment initiation on HIV infection rate and healthcare costs in the UK. Poster Presentation at HIV Drug Therapy Congress, Glasgow, UK 2018.